La vendita allo scoperto per BioVie dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di BioVie. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

BioVie (NASDAQ:BIVI) Azioni, Report sulle vendite allo scoperto

BioVie

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>) shares are rising in Thursday&#8217;s after-hours session after the Federal Communications Commission approved the company&#8217;s <a href="https://www.benzinga.com/general/entertainment/24/07/39668270/paramount-analysts-size-up-merger-skydance-aims-for-earnings-not-a-breakup-redstone-says-co">merger with Skydance Media</a>.
Check out the current <a href="https://www.benzinga.com/quote/PARA">PARA stock price here</a>.
What To Know: The FCC<a href="https://docs.fcc.gov/public/attachments/DOC-413229A1.pdf"> granted</a> the necessary approvals to allow Paramount to complete its planned $8 billion merger with Skydance. 
The FCC approved license transfers for 28 local TV stations&nbsp;owned by CBS after Skydance pledged to hire an ombudsman&nbsp;to review complaints regarding bias concerns at CBS and to&nbsp;eliminate diversity, equity and inclusion (DEI) programs.
"Americans no longer trust the legacy national news media to report fully, accurately and fairly. It is time for a change. That is why I welcome Skydance's commitment to make significant changes at the once storied CBS broadcast network,&#8221; FCC chairman Brendan Carr said in a statement.
&#8220;In particular, Skydance has made written commitments to ensure that the new company's programming embodies a diversity of viewpoints from across the political and ideological spectrum. Skydance will also adopt measures that can root out the bias that has undermined trust in the national news media.&#8221;
The approval comes more than a year after Skydance announced plans to acquire Paramount Global and its subsidiaries.
PARA Price Action: <a href="http://benzinga.com/quote/PARA">Paramount Global</a> shares were up 2.41% in after-hours, trading at $13.58 at the time of publication on Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46615709/south-park-goes-anti-trump-with-satan-jesus-president-white-house-says-show-hasnt-been-relevant-for-20-years">South Park Goes Full Anti-Trump In New Episode With Satan, Jesus &amp; The President: White House Says Show &#8216;Hasn&#8217;t Been Relevant&#8217; For 20+ Years</a></li>
</ul>
Photo: Shutterstock.

Entertainment

Government

News

Regulations

After-Hours Center

Movers

PARA

Paramount Global Stock Jumps After FCC Approves $8 Billion Merger With Skydance

SouthState (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSB#NYSE">SSB</a>) has outperformed the market over the past 5 years by 1.39% on an annualized basis producing an average annual return of 15.97%. Currently, SouthState has a market capitalization of $9.95 billion. 
Buying $100 In SSB: If an investor had bought $100 of SSB stock 5 years ago, it would be worth $208.79 today based on a price of $98.00 for SSB at the time of writing.
<h3>SouthState's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753395317_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $100 Invested In SouthState 5 Years Ago Would Be Worth Today

Colabor Group (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GCL#TSX">GCL</a>) reported quarterly losses of $(0.02) per share. This is a 200 percent decrease over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $169.482 million which missed the analyst consensus estimate of $176.000 million by 3.70 percent. This is a 5.09 percent increase over sales of $161.278 million the same period last year.

Earnings

Earnings Misses

TSX:GCL

Colabor Group Q2 GAAP EPS $(0.02) Down From $0.02 YoY, Sales $169.482M Miss $176.000M Estimate

Liberty Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LBRT#NYSE">LBRT</a>) reported quarterly earnings of $0.12 per share which missed the analyst consensus estimate of $0.15 by 21.05 percent. This is a 80.33 percent decrease over earnings of $0.61 per share from the same period last year. The company reported quarterly sales of $1.043 billion which beat the analyst consensus estimate of $1.007 billion by 3.60 percent. This is a 10.09 percent decrease over sales of $1.160 billion the same period last year.

Earnings Beats

LBRT

Liberty Energy Q2 Adj. EPS $0.12 Misses $0.15 Estimate, Sales $1.043B Beat $1.007B Estimate

SAN JOSE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>) ("the Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that Larry L. Wood will join the Company as president and CEO effective September 2, 2025. Dr. Reza Zadno will retire as president, CEO, and director effective September 1, 2025.
Since 2020, Dr. Zadno has led the Company through significant growth and commercial expansion, including adoption and utilization of Aquablation&#xAE; therapy for the treatment of BPH, the Company's successful 2021 public offering, and the start of clinical trials for the treatment of prostate cancer.
"On behalf of the board of directors, I want to thank Reza for his dedication to the Company and its mission over the past five years," said Thomas M. Prescott, PROCEPT BioRobotics chairperson. "Reza's deep understanding of the potential of the Company's novel technology to redefine the standard of care for BPH and steadfast leadership through key milestones have paved the way for even greater growth and opportunity ahead."
"The last five years have been among the most rewarding of my career and I am very proud of what our team has achieved," said Dr. Reza Zadno, PROCEPT BioRobotics president and CEO. "We grew the number of global Aquablation procedures from a few hundred to nearly one hundred thousand, raised more than $600M capital to support our continued growth, significantly increased enterprise value, and most importantly, we have changed the treatment landscape for patients suffering from BPH and the doctors who treat them. We are just scratching the surface of what's possible, and I am thrilled to pass the torch to Larry Wood to lead the next phases of the Company's exciting journey."
Mr. Wood is an accomplished executive leader with more than 40 years of experience in the medical technology industry at both Edwards Lifesciences and Baxter Healthcare Corporation. He is joining PROCEPT BioRobotics from Edwards, where he has served as corporate vice president and group president, Transcatheter Aortic Valve Replacement and Surgical Structural Heart, since 2023. Prior to that, he was corporate vice president, Transcatheter Aortic Valve Replacement and earlier in his career at Edwards, he held key positions in manufacturing management, regulatory affairs and strategic and clinical marketing, primarily in the company's leading surgical heart valve franchise. In 2024, he joined PROCEPT BioRobotics' board of directors and is a member of its audit committee. Mr. Wood has an M.B.A. from Pepperdine Graziadio Business School.
Mr. Prescott continued, "Larry's strengths and vast experience in the medical technology industry are a great fit with the opportunities ahead for PROCEPT BioRobotics. Larry has demonstrated outstanding leadership and business acumen in one of the most clinically demanding medical device product categories and is known for championing technologies that can significantly benefit patients. At Edwards, Larry and his team revolutionized how patients with severe aortic stenosis are treated. We are excited to have Larry join the Company as CEO, especially after having the opportunity to get to know him, his leadership style, and his insights during his tenure on the PROCEPT BioRobotics board."
"I am honored to join PROCEPT BioRobotics at such a pivotal time in the Company's growth," said Mr. Wood. "The Company's innovative approach to treating prostate disorders has the potential to transform the standard of care for patients worldwide. I look forward to leading this exceptional team and building on their many successes to continue to improve treatment outcomes for doctors and their patients."
In connection with today's announcement the Company is also pre-announcing second quarter of 2025 revenue of approximately $79.2 million. PROCEPT BioRobotics will report second quarter of 2025 earnings results after market close on Wednesday August 6, 2025. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

General

PRCT

PROCEPT BioRobotics Announces Preliminary Q2 Revenue Of ~$79.2M

Management

PROCEPT BioRobotics Dr. Reza Zadno To Retire As President And CEO, Effective September 1, 2025; Larry L. Wood Named New President And CEO Effective September 2, 2025

SB Finl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFG#NASDAQ">SBFG</a>) reported quarterly earnings of $0.58 per share which beat the analyst consensus estimate of $0.54 by 7.41 percent. This is a 26.09 percent increase over earnings of $0.46 per share from the same period last year. The company reported quarterly sales of $17.216 million which beat the analyst consensus estimate of $13.760 million by 25.12 percent. This is a 22.58 percent increase over sales of $14.045 million the same period last year.

SBFG

CORRECTION: SB Finl Gr Q2 Adj. EPS $0.58 Beats $0.54 Estimate, Sales $17.216M Beat $13.760M Estimate

Looking into the current session, LTC Properties Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTC#NYSE">LTC</a>) shares are trading at $35.55, after a 0.08% spike. Moreover, over the past month, the stock spiked by 2.10%, but in the past year, fell by 6.82%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1753394421_0_0.png" alt="Past Year Chart" />

<h3>Evaluating LTC Properties P/E in Comparison to Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 71.15 in the Helath Care REITs industry, LTC Properties Inc. has a lower P/E ratio of 18.4. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1753394421_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

A Look Into LTC Properties Inc's Price Over Earnings

TJX Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) has outperformed the market over the past 15 years by 5.75% on an annualized basis producing an average annual return of 18.12%. Currently, TJX Companies has a market capitalization of $140.87 billion. 
Buying $1000 In TJX: If an investor had bought $1000 of TJX stock 15 years ago, it would be worth $12,339.12 today based on a price of $126.27 for TJX at the time of writing.
<h3>TJX Companies's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753394421_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In TJX Companies 15 Years Ago Would Be Worth This Much Today

Heritage Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTBK#NASDAQ">HTBK</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.19 by 10.53 percent. This is a 40 percent increase over earnings of $0.15 per share from the same period last year. The company reported quarterly sales of $47.782 million which beat the analyst consensus estimate of $45.282 million by 5.52 percent. This is a 14.50 percent increase over sales of $41.731 million the same period last year.

HTBK

CORRECTION: Heritage Commerce Q2 Adj. EPS $0.21 Beats $0.19 Estimate, Sales $47.782M Beat $45.282M Estimate

<a href="https://variety.com/2025/tv/news/fcc-approves-paramount-skydance-merger-deal-conditions-1236459974/">https://variety.com/2025/tv/news/fcc-approves-paramount-skydance-merger-deal-conditions-1236459974/</a>

'FCC Approves Paramount-Skydance Deal After Skydance's CBS Ombudsman, Anti-DEI Pledges'- Variety

Deutsche Boerse (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DBOEY#OTC">DBOEY</a>) reported quarterly earnings of $0.34 per share. This is a 9.68 percent increase over earnings of $0.31 per share from the same period last year. The company reported $1.706 billion in sales this quarter. This is a 9.45 percent decrease over sales of $1.884 billion the same period last year.

DBOEY

Deutsche Boerse Q2 Adj. EPS $0.34 Up From $0.31 YoY, Sales $1.706B Down From $1.884B YoY

GREENFIELD, Ind., July 24, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) announced today that Zenrelia&#x2122; (ilunocitinib) has received approval by the European Commission.
&nbsp;
This approval by the EU reinforces Zenrelia's status as a highly effective, convenient, and safe once-daily oral JAK inhibitor. Zenrelia's approval represents a significant milestone in the EU canine dermatology market, offering a once-daily tablet solution for control pruritus (itching) associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
"Our EU approval for Zenrelia is a pivotal achievement, making it our most rapidly expanding product and solidifying our position as a leader in pet health innovation," stated Dr. Ellen de Brabander, Executive Vice President of Innovation and Regulatory Affairs at Elanco. "We've seen remarkable results from our rigorous head-to-head study against the market leader and in real-world settings where Zenrelia is already approved and being used. We're excited to provide veterinarians across the EU with this impactful solution, offering relief to countless dogs suffering from itchy and inflamed skin."
Elanco is pleased the label is consistent with other markets outside North America where the product has already been approved. Zenrelia is available in Brazil, Canada, Japan and the United States, and the company expects additional approvals in key geographies.
"We're excited to bring Zenrelia to veterinarians and pet owners in Europe and provide a new solution to bring relief to itchy dogs, while changing the standard of care to a single daily dose," said Ramiro Cabral, Executive Vice President, Elanco International. "Our commercial teams are ready and product launch will begin immediately, with supply availability expected in the third quarter. Zenrelia joins our growing pet health portfolio in Europe, including AdTab, Credelio, Galliprant and others."
As part of the EU approval process, Elanco conducted a head-to-head non-inferiority study versus the marketplace incumbent, Apoquel. The randomized, double-blind study of 338 client-owned dogs with confirmed atopic dermatitis was conducted across 25 study sites in four countries. The study shows one daily dose of Zenrelia is at least as effective as the market incumbent JAK inhibitor at the primary end point on Day 28. The study is published in a leading peer-reviewed, international journal, Veterinary Dermatology: <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4475126-1&amp;h=653960695&amp;u=https%3A%2F%2Fonlinelibrary.wiley.com%2Fdoi%2F10.1111%2Fvde.13319&amp;a=https%3A%2F%2Fdoi.org%2F10.1111%2Fvde.13319.">https://doi.org/10.1111/vde.13319.</a>
Details on the marketing authorization will be shared on the European Commission website in the coming days.
ABOUT ELANCO

ELAN

Elanco Animal Health Receives Approval From The European Commission For Zenrelia; Zenrelia To Launch Immediately In Market By Q3 2025

MRBK

Meridian Q2 EPS $0.49 Beats $0.42 Estimate, Sales $32.447M Beat $29.782M Estimate

Ikena Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKNA#NASDAQ">IKNA</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.14) by 57.14 percent. This is a 78.57 percent increase over losses of $(0.28) per share from the same period last year.

IKNA

Ikena Oncology Q2 EPS $(0.06) Beats $(0.14) Estimate

Mr. Cooper Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NASDAQ">COOP</a>) has outperformed the market over the past 5 years by 47.38% on an annualized basis producing an average annual return of 61.97%. Currently, Mr. Cooper Gr has a market capitalization of $10.01 billion. 
Buying $100 In COOP: If an investor had bought $100 of COOP stock 5 years ago, it would be worth $1,160.09 today based on a price of $156.38 for COOP at the time of writing.
<h3>Mr. Cooper Gr's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753393524_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COOP

Here's How Much You Would Have Made Owning Mr. Cooper Gr Stock In The Last 5 Years

Scholastic Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCHL#NASDAQ">SCHL</a>) shares are climbing after the company released its second-quarter results after Thursday's closing bell. Here's a look at the key figures <a href="https://www.benzinga.com/pressreleases/25/07/n46616156/scholastic-reports-fourth-quarter-and-fiscal-2025-results">from the quarter.&nbsp;&nbsp;</a>
Check out the current price of <a href="https://www.benzinga.com/quote/SCHL">SCHL stock here</a>.
The Details:&nbsp;Scholastic&nbsp;reported quarterly adjusted earnings of 87 cents per share, which beat the 85 cent analyst consensus estimate. Quarterly revenue came in at $508.3 million, beating the&nbsp;$494.58 million Street estimate.
Read Next:&nbsp; <a href="https://www.benzinga.com/markets/tech/25/07/46505139/quantum-stock-tracker-rigetti-achieves-major-breakthrough-but-jim-cramer-names-another-stock-to-own?utm_source=articleShare">Quantum Stock Tracker: Rigetti Achieves Major Breakthrough, But Jim Cramer Names Another Stock To &#8216;Own&#8217;</a>
&#8220;Scholastic delivered solid financial results in fiscal 2025, with strong Adjusted EBITDA in line with our original guidance,&#8221; CEO Peter Warwick said. 
&#8220;In the fourth quarter, continued strength in Children&#8217;s Book Publishing and Distribution, combined with successful execution and disciplined cost management, helped offset macroeconomic pressures on school spending, which continued to impact the Education division,&#8221; Warwick added. 
Outlook:&nbsp;Scholastic said it expects &#8220;significant growth&#8221; in fiscal 2026 Adjusted EBITDA to&nbsp;$160 million&nbsp;to&nbsp;$170 million, reflecting strength in its core businesses and cost savings, partly offset by continued headwinds on school spending.
Revenue is expected to grow 2% to 4% in fiscal 2026.&nbsp;
SCHL Price Action: According to data from<a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw"> Benzinga Pro</a>, Scholastic stock was up 12.39% at $24.22 in Thursday's extended trading.&nbsp;
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/space/25/07/46534529/space-stock-tracker-virgin-galactic-makes-a-comeback-while-rocket-lab-takes-a-breather?utm_source=articleShare">Space Stock Tracker: Virgin Galactic Makes A Comeback While Rocket Lab Takes A Breather</a></li>
</ul>
Photo: Shutterstock

Education

SCHL

Scholastic Stock Soars After Q4 Results Are At Head Of The Class

Hammond Power Solns (TSX:<a class="ticker" href="https://www.benzinga.com/stock/HPS#TSX">HPS</a>) reported quarterly earnings of $1.72 per share which beat the analyst consensus estimate of $1.70 by 1.18 percent. This is a 13.13 percent decrease over earnings of $1.98 per share from the same period last year. The company reported quarterly sales of $224.419 million which beat the analyst consensus estimate of $215.567 million by 4.11 percent. This is a 13.80 percent increase over sales of $197.212 million the same period last year.

TSX:HPS

TSX:HPS.A

Hammond Power Solns Q2 Adj. EPS $1.72 Beats $1.70 Estimate, Sales $224.419M Beat $215.567M Estimate

Guidance

INTC

During Conference Call, Intel Exec Says Anticipate 2025 Gross Capital Investment Will Be ~$18B

Pinetree Cap (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PNP#TSX">PNP</a>) reported quarterly losses of $(0.18) per share. This is a 80 percent decrease over losses of $(0.10) per share from the same period last year. The company reported $(913.000 thousand) in sales this quarter. This is a 13.14 percent decrease over sales of $(807.000 thousand) the same period last year.

TSX:PNP

Pinetree Cap Q2 GAAP EPS $(0.18) Down From $(0.10) YoY, Sales $(913.000K) Down From $(807.000K) YoY

Legal

Press Releases

BIOVIE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioVie Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth

BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025)

Health Care

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025

BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress

BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)

BioVie Announces Data Highlighting Bezisterim's Potential to Slow or Reverse Biological Aging and Neurodegeneration Featured as a Keynote Talk at the 7th World Aging and Rejuvenation Conference

BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors

BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology

Comments

BioVie

Vendite allo scoperto

BioVie (NASDAQ:BIVI) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO